Condition (MeSH)
Amaurosis Fugax
ClinicalTrials.gov lists 3 trials for Amaurosis Fugax or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
3 of the 3 trials are tagged with Amaurosis Fugax itself; the rest are tagged with a narrower condition beneath it.
When did Amaurosis Fugax trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2013 | 2 |
| 2011 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Amaurosis Fugax trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 1 |
| Observational | 1 |
How many Amaurosis Fugax trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Amaurosis Fugax trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Abbott Medical Devices | 1 |
| AdvanceCor GmbH | 1 |
Which serious adverse events do Amaurosis Fugax trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypotension | 69 | 2 |
| Arrhythmia (Includes Brady And Tachy) | 28 | 1 |
| Cerebrovascular accident - Minor Ischemic Ispilateral | 23 | 1 |
| Other | 18 | 1 |
| Transient Ischemia Attack | 13 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Amaurosis Fugax? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Serial carotid MRI identifies rupture of a vulnerable plaque resulting in amaurosis fugax. | Neurology | 2013 | Yes |
| Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. | Journal of vascular surgery | 2005 | Yes |
| Comparison of risk factors in patients with transient and prolonged eye and brain ischemic syndromes. | Stroke | 2002 | Yes |
| Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. | Journal of vascular surgery | 2010 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.